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Recognition, evaluation, and treatment of heart failure are
essential components of clinical cardiology practice. In order to
achieve competency in this subject, 3 distinct training levels are
defined, with curriculum outlined, in this section (1–4). All
cardiology fellowship training programs will provide, at the
least, a Level 1 curriculum in heart failure. More specifically,
Level 1 training will provide an understanding of the depth and
breadth of the heart failure syndrome, as well as nuances of
therapy including the important topic of heart failure preven-
tion. Level 2 training will be for those individuals who wish to
broaden their experience with heart failure patients, particularly
those with more advanced and challenging syndromes. This
curriculum can, in particular, provide the opportunity to learn
to manage devices (other than circulatory support systems)
implanted for heart failure therapy and arrhythmia or hemo-
dynamic monitoring. Level 2 will also emphasize more detailed
hemodynamic assessment of these patients. Level 3 training
will be for those who anticipate focusing the majority of their
subsequent clinical or research activities on the syndrome of
heart failure with a curriculum requiring an additional 12
months of fellowship training above and beyond that required
for cardiology specialization board examination. It is recog-
nized that not all cardiology fellowship training programs will
be capable of providing the most intense Level 3 training
curriculum. Level 3 training will offer a range of programs that
might, for example, include heart transplantation, mechanical
circulatory support devices, and advanced heart failure electro-
physiology, although not necessarily all of these.
383JACC Vol. 51, No. 3, 2008 Young et al.
January 22, 2008:383–9 ACCF COCATS 3 Training Statement: Task Force 8
This training scheme recognizes the fact that today, there
is an ever-increasing number of treatments and interven-
tions that improve outcomes and significantly alter the
course of the heart failure syndrome. These treatments have
generally increased the complexity of care, and it has
become clear that there is a need for additional and special
expertise to best effect and improve utilization of many heart
failure evaluation and treatment strategies. It is also recog-
nized that a significant portion of initial and follow-up care
for heart failure patients will continue to be under the
purview of general cardiologists and primary care clinicians;
however, the more advanced Level 2 and 3 programs will
provide increased sophistication and more skills necessary to
manage advanced heart failure syndromes.
It is important to point out that Level 3 training and
subsequent competency does not necessarily require the
same level of experience with cardiac transplantation re-
quired for qualification as a heart transplant physician under
United Network of Organ Sharing (UNOS) criteria (5). It
is anticipated that a much broader group of individuals will
be interested in establishing competency in advanced heart
failure cardiology than will be directly managing patients
undergoing cardiac transplantation. Nonetheless, many pro-
grams will offer an experience within the Level 3 curriculum
that can establish heart transplant physician competency
according to UNOS criteria. Furthermore, in developing
Level 3 heart failure training criteria there was an expecta-
tion that, at some point in time, a secondary subspecialty of
advanced heart failure management would likely evolve.
Although timing for such a proposal moving forward is
unclear, it is desirable to anticipate a curriculum that would
qualify individuals for this distinction. The cumulative
duration for training in heart failure will then be 1 month
for Level 1 taken as part of 9 months of required nonlabo-
ratory clinical practice rotation, and it is assumed that
trainees will obtain additional training in heart failure
preventive cardiovascular medicine beyond the 1-month
core training as part of the experience during other clinical
months such as consult services and the coronary care unit.
Level 2 will require 6 months of dedicated rotations during
the 36-month clinical cardiology training period, and Level
3 will require 12 months beyond the basic 36-month core
training program (Table 1).
Training in Heart Failure
Level 1: General Training
The fundamental concepts of heart failure’s pathophysiol-
ogy and its treatment should be understood by all trainees in
cardiovascular medicine as part of the core Level 1 training
curriculum. Training in the clinical management of heart
failure should include supervised experience in both inpa-
tient and outpatient settings, and will expose the trainee to
a broad spectrum of underlying causes of heart failure.
Trainees should be well acquainted with the nuances of
therapy for heart failure that are specific to different etiol-
ogies and should be well informed about the pharmacology
of standard cardiovascular drugs used to treat heart failure.
Trainees should be equally aware of the treatment strategies
for patients with both chronic disease and acute exacerba-
tions. An important element of the curriculum will be to
train clinicians to appropriately refer heart failure patients
for pacemaker, defibrillator, and percutaneous cardiovas-
cular interventions; surgical procedures (including inser-
tion of mechanical circulatory support devices); and
cardiac transplantation.
Heart Failure Level 1 Training Curriculum:
Core Curriculum
The heart failure training Level 1 curriculum must include
the following to ensure that trainees have formal instruction
and clinical experience in the evaluation and management of
patients from each of the following categories (it is antici-
pated that training programs will provide that experience in
a creative combination of emergency department, inpatient,
and outpatient settings):
1. Neurohormonal activation and its importance in the
development of cardiovascular pathology and the syn-
drome of heart failure
2. The concept and significance of ventricular remodeling
Summary of Training Requirements for Heart Failure
Table 1 Summary of Training Requirements for Heart Failure
Task Force Area Level
Minimal Number
of Procedures
Cumulative Duration
of Training (Months)
Minimal Cumulative
Number of Cases Comments
8 Heart failure and
transplantation
1
2
3
1*†
6
12
*Can be taken as part of 9 months
of required nonlaboratory
clinical practice rotation.
†It is assumed that trainees will
obtain additional training in
heart failure and preventive
cardiovascular medicine beyond
the 1-month core training as
part of the experience during
other clinical months, such as
consult services and coronary
care unit.
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3. Cardiomyocyte biology as it applies to heart failure,
focusing on the underlying abnormalities in the myo-
cytes of the failing heart
4. Patients with heart failure with dilated or nondilated
ventricles
5. Patients with new onset heart failure
6. Patients with acute decompensation of chronic heart
failure
7. Geriatric patients with heart failure
8. Patients with heart failure associated with cancer
chemotherapy
9. Patients with heart failure who are pregnant or recently
post-partum
10. Patients with heart failure and congenital heart disease
11. Patients with heart failure representing diverse ethnic
groups, with attention to specific diagnostic and ther-
apeutic issues within these groups
12. Men and women with heart failure
13. Patients with heart failure before and after cardiac and
noncardiac surgery
14. Patients with inherited forms of cardiomyopathy
15. Patients with hypertrophic cardiomyopathy
16. Patients with infiltrative and inflammatory cardiomy-
opathies
17. Patients with heart failure and atrial and ventricular
arrhythmias
18. Patients with heart failure due to pulmonary pathology
These scenarios represent a broad and basic spectrum of
clinical heart failure, and it is anticipated that most cardi-
ology fellowship training programs will have the ability to
meet this criteria. However, it is accepted that for some
specific situations (i.e., heart failure patients with congenital
heart disease or pregnancy-related heart failure states) clin-
ical material may not be readily available. In those specific
situations didactic training would be an acceptable substi-
tute for formal inpatient or outpatient clinical exposure.
EVALUATION OF HEART FAILURE
With respect to evaluation of patients with heart failure,
trainees must have formal instruction and clinical experience
in the following specific areas:
1. Clinical trial evidence with respect to the diagnosis of
heart failure
2. Clinical features (history and physical exam) in all forms
and etiologies of heart failure
3. Application and interpretation of approaches to evalu-
ating symptom severity, functional capacity, and health-
related quality of life in patients with heart failure
4. Exercise physiology, including the role and interpreta-
tion of maximal and submaximal exercise testing and
cardiopulmonary exercise testing
5. Indications for, and interpretation of, results of all
diagnostic tests and modalities relevant to evaluation
and management of patients with, or suspected of
having, heart failure or cardiac dysfunction; in particu-
lar, the impact of such testing on the management of
these patients
6. Evaluation of the patient presenting with new onset
heart failure and with acute exacerbation of chronic
heart failure, including differential diagnosis, specific
etiologies, and exacerbating factors
7. Role and interpretation of hemodynamic monitoring
and its use in managing patients with new onset heart
failure or exacerbation of chronic heart failure
8. Indications for referral of patients for mechanical circu-
latory support and cardiac transplantation
9. Indications for and evaluation of patients for implantation
of left ventricular assist devices as destination therapy
HEART FAILURE MANAGEMENT
With respect to managing patients with heart failure,
fellows must have formal instruction and clinical experience
in the following specific areas:
1. Clinical trial evidence relevant to the management of
heart failure
2. Indication, prescription, pharmacology, adverse effects,
and appropriate monitoring of all classes of drugs
relevant to the heart failure patient, including those
known to benefit patients with heart failure, those
suspected of benefiting patients with heart failure, and
those known or suspected of adversely affecting patients
with heart failure, in both the acute and chronic setting
3. Indication and prescription of nonpharmacologic/non-
device treatment modalities in heart failure, including
diet and exercise
4. Indications for cardiac transplant
5. Evidence for differences in appropriate management
and response to therapy based on differences in etiology,
cardiac structure and function, age, gender, ethnic
background, and comorbidity
6. Impact of psychosocial factors on the manifestations,
expression, and management of heart failure
PREVENTION OF HEART FAILURE
With respect to heart failure prevention, trainees must have
formal instruction regarding conditions and factors known
to predispose to, or exacerbate, heart failure syndromes.
Specifically, a curriculum that emphasizes comprehensive
cardiovascular risk factor modification more generally (e.g.,
prevention of atherosclerosis), and with respect to the heart
failure syndrome, specifically, will be required.
Level 2: Intensified Experience in Heart Failure
Trainees who wish to have more training in advanced heart
failure should be enrolled in programs that include specific
outpatient clinics and inpatient services designed for pa-
tients requiring therapy for heart failure, as described for
Level 1. However, such programs, in addition to ensuring a
curriculum that satisfies the specifics of Level 1 training,
also must offer a greater intensity and exposure to a broader
spectrum of heart failure therapy modalities. Level 2 train-
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ing can be accomplished within the scope of the 3 years of
initial cardiology training. Trainees in a Level 2 curriculum
should actively participate in didactic activities relating more
specifically to heart failure, including research conferences,
seminars, and journal clubs with the heart failure syndrome
their primary focus.
Heart Failure Level 2 Training Curriculum:
Additional Elements
In addition to satisfying all Level 1 curriculum requirements
outlined in the previous text, trainees will be required to
have additional experiences in the interpretation of ad-
vanced heart failure patient hemodynamic data during both
acute and chronic interventions and during the assessment
of prognosis. One example of an additional curriculum at
the Level 2 stage would be trainee rotations through
outpatient electrophysiology clinics to focus on the interro-
gation, evaluation, and programming of implantable elec-
trophysiologic devices used to treat and manage heart failure
patients.
Level 3: Advanced Training in Heart Failure
In addition to demonstrating proficiency in the specified
and required Level 1 and elective Level 2 curriculum,
advanced Level 3 training requires further demonstration of
proficiency in additional arenas that include exposure to
patients with more advanced or challenging heart failure
conditions. Level 3 curriculum training will require an
additional 12 months of training above and beyond that
required for basic cardiology fellowship. A variety of curric-
ulums can be created to satisfy Level 3 training require-
ments, but at the core of all will be the following required
components:
Basic Mechanisms of Heart Failure
In addition to the curriculum specified in Level 1 training,
fellows should have formal instruction and attain under-
standing of the following to be considered a more advanced
Level 3 clinician:
1. More advanced training in cardiomyocyte and extracel-
lular matrix biology, including calcium dysregulation;
mechanisms of arrhythmia generation; beta-receptor
abnormalities; mechanisms of apoptosis; metabolic ab-
normalities of the failing myocyte; and the roles of
matrix remodeling in the progression of heart failure
2. Genetics, including a) common mutations leading to
hypertrophic and dilated cardiomyopathies and b) an
understanding of genetic polymorphisms related to myo-
cardial disease and to targeted heart failure treatment
Heart Failure Disease Management
To qualify for heart failure Level 3 training, fellows must
have a more in-depth and formal instruction in heart failure
disease management, have clinical experience, and demon-
strate proficiency as part of a multidisciplinary care team in
a clinical setting dedicated to heart failure. Managing
multidisciplinary heart failure clinics and home-based care
services is envisioned as a primary role of the advanced heart
failure cardiologist, who should achieve proficiency in:
1. Specific behavioral strategies to enhance adherence to a
heart failure therapeutic regimen
2. Supervision of home-based titration and monitoring of
diuretics and neurohormonal antagonists with surveil-
lance for renal dysfunction and electrolyte disturbances
3. The comprehensive education and counseling needs of
heart failure patients and family members
4. Education and counseling strategies
5. The importance of nonpharmacologic, as well as phar-
macologic, management
6. End-of-life care, including care options and participa-
tion in a multidisciplinary palliative care team
7. Assessment for quality of life, psychological problems
(e.g., anxiety and depression), cognitive impairment,
literacy problems, social isolation, financial problems,
and other barriers to adherence and risk factors for
rehospitalization
8. Management of heart failure with multiple comorbidities
9. Collaboration with nurses, dietitians, social workers,
pharmacists, and other health professionals in the
management of patients to stabilize or improve health
status and prevent hospitalization
10. Transitional care principles, that is, facilitating commu-
nication between caregivers and physician extenders
Clinical Research
The heart failure Level 3 training assumes a more in-depth
understanding of research in the heart failure field. Trainees
at this level, therefore, should have a thorough knowledge
and understanding of the principles of clinical research,
sufficient to fully evaluate the validity and relevance of
clinical research findings. This understanding should come
from both didactic instruction and participation in clinical
research projects as a trainee. Level 3 curriculum should
ensure that training includes insight into:
1. Principles of informed consent and the ethical conduct
of clinical research
2. Basic statistical methodologies, including sample size
estimation and evaluation of significance
3. An understanding of the advantages and disadvantages
of various clinical trial designs
4. Understanding of the various end points employed in
clinical investigation in heart failure, including those
employed for the measurement of clinical outcomes,
functional status, and symptoms, as well as use of
surrogate and composite end points
5. An understanding of the impact and interpretation of
testing multiple end points simultaneously
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Expanded Heart Failure Populations
Advanced training further requires demonstration of profi-
ciency in the management of additional more challenging
cohorts of heart failure patients (with the specified levels of
exposure listed in parentheses if meeting UNOS criteria as a
“heart transplant physician” is desired). It is recognized that not
all programs offering Level 3 training will have heart transplant
or mechanical circulatory support programs that will satisfy
UNOS criteria for heart transplant physician designation.
1. Patients requiring end-of-life hospice-based care
2. Patients with hemodynamic compromise severe enough
to warrant chronic inotropic drug infusion support
3. Patients with heart failure and noncardiac organ trans-
plants
4. Patients who are being evaluated for cardiac transplant
or mechanical assist devices (at least 30)
5. Patients who have undergone cardiac transplant (at least
30, of whom at least 5 are seen during initial transplant
hospitalization)
6. Patients with heart failure on mechanical circulatory
assist devices (at least 5, of whom at least 2 are being
managed during perioperative hospitalization)
7. Patients with heart failure being evaluated for implant-
able cardioverter-defibrillators (ICDs) (at least 50) and
patients with heart failure being evaluated for cardiac
resynchronization therapy (CRT) (at least 50)
8. Device interrogation and interpretation in patients with
implanted ICD or ICD-CRT devices (at least 100)
Additional Training Within a Level 3 Curriculum
For select individuals trained in advanced heart failure
cardiology, it may be desirable to achieve additional training
and credentialing. Examples of this include areas such as
cardiac transplantation and mechanical circulatory support
devices (as previously discussed), electrophysiologic device
implants, and more sophisticated cardiovascular imaging. It
is recognized that training programs may choose to incor-
porate opportunities for achieving competencies in these
areas, either concurrently or consecutively with the 12-
month Level 3 requirements, which are consistent with
those training requirements specified elsewhere in this
document. Further, as these fields evolve, combination
programs may be established that are specifically designed to
provide for joint competencies in these and other areas.
Summary
Training in heart failure can be segregated into 3 distinct
and ascending or tiered levels of intensity. Level 1 represents
the basic training and competency that every cardiology
fellowship trainee must experience and demonstrate. Level 2
training represents a significant intensification of training,
so that a trainee can subsequently focus some of his or her
subsequent clinical activities on heart failure patients or
research. Level 3 training offers competencies required for
individuals specializing in advanced heart failure cardiology.
Such competency includes advanced training in such areas
as cardiac transplantation, ventricular assist devices, and
heart failure disease management. Many programs will offer
exposure sufficient to qualify the trainee for the UNOS
designation of heart transplant physician in the Level 3
curriculum. Within this rapidly evolving field, in which new
diagnostic and treatment modalities are emerging, over
time, additional competencies may be warranted to supple-
ment present training and competency standards.
doi:10.1016/j.jacc.2007.11.016
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Dr. William T.
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● AstraZeneca
● Boehringer-Ingelheim
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● GlaxoSmithKline
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None None
This table represents the relationships of committee members with industry that were reported by the authors as relevant to this topic. It does not necessarily reflect relationships with industry at the time
of publication.
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Remarkable advances in surgical and catheter management
of congenital heart disease (CHD) over the last half century
have allowed greater than 85% of children with CHD to
survive to adulthood (1). It is estimated that there are now
over 1 million adult survivors with CHD in North America
alone; thus, there are now more adults than children with
CHD in the United States, and the number appears to be
growing by about 5% per year (2). Adults with CHD have
special health care needs and often present complex com-
binations of problems that are generally unrecognized by
those in a traditional internal medicine–based cardiology
training program (3). Medical cardiologists are experts in
the care of adult-acquired diseases that affect the heart and
circulation, but currently most have little or no training in
CHD, particularly in complex disorders. Adult CHD and
clinical experiences for cardiology fellows vary widely (4).
Many adults with CHD continue to be cared for by
pediatric cardiologists because the numbers of medical
cardiologists specializing in this complicated field are few
and insufficient (5,6). This report suggests an approach to
more systematic training of medical cardiologists in the
recognition and care of adults with CHD based upon
previous Bethesda Conference descriptions of workforce
needs and educational requirements (6).
389JACC Vol. 51, No. 3, 2008 Child et al.
January 22, 2008:389–93 ACCF COCATS 3 Training Statement: Task Force 9
